Research

 

Journal of Clinical Oncology

 

Treatment of metastatic renal cancer with high-dose interleukin-2 after targeted therapy.

Authors: Robert E. Hawkins, Victoria Galvis, Jonathan Shanks, Neha Dalal, Fiona Thistlethwaite, and Andrea Spencer-Shaw

High dose Interleukin 2 (HD IL2) as 1st line treatment in metastatic renal cell carcinoma (mRCC): A 10-year single centre experience.

Authors: Shien Chow, Victoria Galvis, Manon Pillai, Rebecca Leach, Elizabeth Keene, Andrea Spencer-Shaw, Liptrot Tom, Jonathan Shanks, Alaaeldin Shablak, Fiona Thistlethwaithe, and Robert E. Hawkins

 

 

10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).

Authors: Shien Chow, Manon Rhys Pillai, Victoria Galvis, Rebecca Leach, Elizabeth Keene, Kevin Chan, Andrea Spencer-Shaw, Fiona Thistlethwaithe, and Robert E. Hawkins

Journal for ImmunoTherapy of Cancer

 

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) – a 10 year single-site experience and outcome of prospective pathology-based patient selection

  • Published: 

Authors: Shien Chow,  Manon Evans, Victoria Galvis, Rebecca Leach, Elizabeth Keene, Kevin Chan, Andrea Spencer-Shaw, Shanks Jonathan, Alaaeldin Shabalak, Fiona Thistlethwaite & Robert Hawkins 

©  2026 Victoria Galvis. Built using WordPress and the Mesmerize Theme